Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Nephrogenic diabetes insipidus Indication Strategy Report 2026: V2R, Trials and Deals
23 July 2026
2026 Nephrogenic diabetes insipidus strategy: epidemiology, V2R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Distal renal tubular acidosis Indication Strategy Report 2026: AE1, Trials and Deals
23 July 2026
2026 Distal renal tubular acidosis strategy: epidemiology, AE1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Liddle syndrome Indication Strategy Report 2026: ENaC, Trials and Deals
23 July 2026
2026 Liddle syndrome strategy: epidemiology, ENaC biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Gitelman syndrome Indication Strategy Report 2026: NCC, Trials and Deals
23 July 2026
2026 Gitelman syndrome strategy: epidemiology, NCC biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Bartter syndrome Indication Strategy Report 2026: NKCC2, Trials and Deals
23 July 2026
2026 Bartter syndrome strategy: epidemiology, NKCC2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Dent disease Indication Strategy Report 2026: CLCN5, Trials and Deals
23 July 2026
2026 Dent disease strategy: epidemiology, CLCN5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Autosomal dominant tubulointerstitial kidney disease Indication Strategy Report 2026: UMOD, Trials and Deals
23 July 2026
2026 Autosomal dominant tubulointerstitial kidney disease strategy: epidemiology, UMOD biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Medullary sponge kidney Indication Strategy Report 2026: CaSR, Trials and Deals
23 July 2026
2026 Medullary sponge kidney strategy: epidemiology, CaSR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Renal artery stenosis Indication Strategy Report 2026: AGT, Trials and Deals
23 July 2026
2026 Renal artery stenosis strategy: epidemiology, AGT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Marfan syndrome Indication Strategy Report 2026: TGFBR2, Trials and Deals
23 July 2026
2026 Marfan syndrome strategy: epidemiology, TGFBR2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Loeys-Dietz syndrome Indication Strategy Report 2026: TGFBR2, Trials and Deals
23 July 2026
2026 Loeys-Dietz syndrome strategy: epidemiology, TGFBR2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Refractory angina Indication Strategy Report 2026: CD34, Trials and Deals
23 July 2026
2026 Refractory angina strategy: epidemiology, CD34 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…